Get the Stockscreener App
287.97
1.54%
4.43
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $287.97, with a volume of 2.02M.
It is up +1.54% in the last 24 hours and down -1.04% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$283.54
Open:
$282.61
24h Volume:
2.02M
Relative Volume:
0.68
Market Cap:
$154.99B
Revenue:
$34.13B
Net Income/Loss:
$5.93B
P/E Ratio:
26.27
EPS:
10.96
Net Cash Flow:
$10.92B
1W Performance:
+5.98%
1M Performance:
-1.04%
6M Performance:
+1.78%
1Y Performance:
-4.35%
1-Day Range:
$281.04
$288.32
1-Week Range:
$273.12
$288.22
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
288.24 | 146.20B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
744.78 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.53 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.63 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.72 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.55 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy - WTAQ
Boston Common Asset Management LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Centre Asset Management LLC Invests $9.06 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Cypress Asset Management Inc. TX Acquires New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Fulcrum Equity Management Cuts Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mattson Financial Services LLC Sells 1,194 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Siemens Fonds Invest GmbH Sells 22,764 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Korea approves Amgen's Imdeltar as first third-line treatment for small cell lung cancer - Chosunbiz
(AMGN) Long Term Investment Analysis - news.stocktradersdaily.com
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Forum Financial Management LP - MarketBeat
Mackenzie Financial Corp Lowers Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
GTS Securities LLC Cuts Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
GF Fund Management CO. LTD. Invests $31.74 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ball & Co Wealth Management Inc. Takes $3.71 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
July 11th Options Now Available For Amgen (AMGN) - Nasdaq
Fairtree Asset Management Pty Ltd Invests $586,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Thoma Capital Management LLC Buys Shares of 2,621 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
PKO Investment Management Joint Stock Co Makes New $5.68 Million Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Anchor Pointe Wealth Management LLC Invests $302,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Lighthouse Financial LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
IronOak Wealth LLC. Invests $313,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Alpha Wealth Funds LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Is Amgen Stock a Buy? - AOL.com
Amgen Inc. (NASDAQ:AMGN) Stock Holdings Trimmed by Toronto Dominion Bank - MarketBeat
Alexion Awarded Injunction Against Amgen In SOLIRIS Patent Action; Court Considers Anticipation By Incorporation By Reference - Mondaq
Amgen Inc. (NASDAQ:AMGN) Shares Sold by JT Stratford LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Vise Technologies Inc. - MarketBeat
Novem Group Invests $328,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Regeneron Trial Team Talks $406.8M Win in Antitrust Trial Showdown With Cholesterol Drug Rival Amgen - Law.com
Cancer Biologics Market Set to Witness High DemandRoche, Amgen - openPR.com
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
1,282 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Kilter Group LLC - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Invests $193.34 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
LM Advisors LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Yoffe Investment Management LLC Makes New $366,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
37,658 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Worldquant Millennium Advisors LLC - MarketBeat
Great Valley Advisor Group Inc. Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
965 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Armis Advisers LLC - MarketBeat
United Advisor Group LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
4,827 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Pacific Point Advisors LLC - MarketBeat
Western Wealth Management LLC Has $1.43 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Parr Mcknight Wealth Management Group LLC Invests $3.75 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s SWOT analysis: biotech giant’s stock faces obesity market challenge By Investing.com - Investing.com India
Amgen’s SWOT analysis: biotech giant’s stock faces obesity market challenge - Investing.com
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Focus Partners Advisor Solutions LLC - MarketBeat
Twinbeech Capital LP Has $1.36 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zacks Research Has Strong Forecast for Amgen FY2025 Earnings - MarketBeat
Expert CFA Committee Flags Amgen as Potentially Undervalued Stock for Investors - Stock Titan
BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN) | AMGN Stock News - GuruFocus
BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN) - New Castle News
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.22%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):